Intellia Therapeutics, Inc. (NTLA)
NASDAQ: NTLA · Real-Time Price · USD
12.17
-0.08 (-0.65%)
At close: Feb 21, 2025, 4:00 PM
12.14
-0.03 (-0.25%)
After-hours: Feb 21, 2025, 6:44 PM EST
Intellia Therapeutics Analyst Ratings
Total Analysts
18
Consensus Rating
Buy
Price Target
$50.53
Upside
+315.20%
Ratings History
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Buy → Hold Downgrades $56 → $11 | Buy → Hold | Downgrades | $56 → $11 | -9.61% | Jan 27, 2025 |
| Goldman Sachs | Goldman Sachs | Hold Maintains $20 → $12 | Hold | Maintains | $20 → $12 | -1.40% | Jan 14, 2025 |
| Oppenheimer | Oppenheimer | Buy Maintains $60 → $40 | Buy | Maintains | $60 → $40 | +228.68% | Jan 13, 2025 |
| Wells Fargo | Wells Fargo | Buy Maintains $70 → $60 | Buy | Maintains | $70 → $60 | +393.02% | Jan 10, 2025 |
| BMO Capital | BMO Capital | Buy Maintains $70 → $50 | Buy | Maintains | $70 → $50 | +310.85% | Jan 10, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $90 | Strong Buy | Maintains | $90 | +639.52% | Nov 19, 2024 |
| Wells Fargo | Wells Fargo | Buy Maintains $80 → $70 | Buy | Maintains | $80 → $70 | +475.18% | Nov 18, 2024 |
| Wedbush | Wedbush | Hold Reiterates $14 | Hold | Reiterates | $14 | +15.04% | Nov 18, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $88 → $91 | Strong Buy | Maintains | $88 → $91 | +647.74% | Nov 18, 2024 |
| Oppenheimer | Oppenheimer | Buy Maintains $70 → $60 | Buy | Maintains | $70 → $60 | +393.02% | Nov 11, 2024 |
| Barclays | Barclays | Buy Maintains $76 → $55 | Buy | Maintains | $76 → $55 | +351.93% | Nov 8, 2024 |
| Citigroup | Citigroup | Hold Maintains $25 → $19 | Hold | Maintains | $25 → $19 | +56.12% | Oct 25, 2024 |
| Goldman Sachs | Goldman Sachs | Hold Maintains $31 → $20 | Hold | Maintains | $31 → $20 | +64.34% | Oct 25, 2024 |
| Baird | Baird | Hold Maintains $24 → $18 | Hold | Maintains | $24 → $18 | +47.90% | Oct 25, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $94 → $88 | Strong Buy | Maintains | $94 → $88 | +623.09% | Oct 24, 2024 |
| RBC Capital | RBC Capital | Buy Reiterates $54 | Buy | Reiterates | $54 | +343.71% | Sep 19, 2024 |
Upgrade to Pro
Get stock forecasts from Wall Street's highest rated professionals
Get much more with Stock Analysis Pro
- Investment ideas from the top Wall Street analysts
- Unlimited access to all data and tools
- Advanced analyst filtering and sorting options
- Up to 10 years of analyst rating history
Analyst Star Rankings
Our analyst star rankings are based on these four factors
- Success Rate
- The percentage of ratings that are profitable.
- Average Return
- The average percentage return within one year of the rating.
- Rating Count
- The more ratings the analyst has provided, the higher the score.
- Recency
- Ratings provided within the past year contribute to a higher score.